Identification of recurrent BRAF non-V600 mutations in intraductal carcinoma of the prostate in Chinese populations
Neoplasia. 2024 Feb 27;50:100983. doi: 10.1016/j.neo.2024.100983. Online ahead of print.ABSTRACTWhile BRAF alterations have been established as a driver in various solid malignancies, the characterization of BRAF alterations in prostate cancer (PCa) has not been thoroughly interrogated. By bioinformatics analysis, we first found that BRAF alterations were associated with advanced PCa and exhibited mutually exclusive pattern with ERG alteration across multiple cohorts. Of the most interest, recurrent non-V600 BRAF mutations were found in 3 of 21 (14.3 %) PCa patients demonstrating IDC-P morphology. Furthermore, experimental...
Source: Neoplasia - February 28, 2024 Category: Cancer & Oncology Authors: Jing Hu Xinyi Chen Feifei Sun Lili Liu Long Liu Zimeng Yang Hanwen Zhang Zeyuan Yu Ru Zhao Yueyao Wang Hui Liu Xiaorong Yang Fusheng Sun Bo Han Source Type: research
Glypican-1-targeted antibody-drug conjugate inhibits the growth of glypican-1-positive glioblastoma
In conclusion, GPC1-ADC demonstrated potent intracranial activity against GPC1-positive glioblastoma in an orthotopic xenograft model. These results indicate that GPC1-ADC could represent a groundbreaking new therapy for treating glioblastoma beyond the BBB.PMID:38417223 | DOI:10.1016/j.neo.2024.100982 (Source: Neoplasia)
Source: Neoplasia - February 28, 2024 Category: Cancer & Oncology Authors: Shun Uchida Satoshi Serada Yuji Suzuki Eiji Funajima Kei Kitakami Kazumasa Dobashi Satomi Tamatani Yuichi Sato Takaaki Beppu Kuniaki Ogasawara Testuji Naka Source Type: research
Identification of recurrent BRAF non-V600 mutations in intraductal carcinoma of the prostate in Chinese populations
Neoplasia. 2024 Feb 27;50:100983. doi: 10.1016/j.neo.2024.100983. Online ahead of print.ABSTRACTWhile BRAF alterations have been established as a driver in various solid malignancies, the characterization of BRAF alterations in prostate cancer (PCa) has not been thoroughly interrogated. By bioinformatics analysis, we first found that BRAF alterations were associated with advanced PCa and exhibited mutually exclusive pattern with ERG alteration across multiple cohorts. Of the most interest, recurrent non-V600 BRAF mutations were found in 3 of 21 (14.3 %) PCa patients demonstrating IDC-P morphology. Furthermore, experimental...
Source: Neoplasia - February 28, 2024 Category: Cancer & Oncology Authors: Jing Hu Xinyi Chen Feifei Sun Lili Liu Long Liu Zimeng Yang Hanwen Zhang Zeyuan Yu Ru Zhao Yueyao Wang Hui Liu Xiaorong Yang Fusheng Sun Bo Han Source Type: research
Glypican-1-targeted antibody-drug conjugate inhibits the growth of glypican-1-positive glioblastoma
In conclusion, GPC1-ADC demonstrated potent intracranial activity against GPC1-positive glioblastoma in an orthotopic xenograft model. These results indicate that GPC1-ADC could represent a groundbreaking new therapy for treating glioblastoma beyond the BBB.PMID:38417223 | DOI:10.1016/j.neo.2024.100982 (Source: Neoplasia)
Source: Neoplasia - February 28, 2024 Category: Cancer & Oncology Authors: Shun Uchida Satoshi Serada Yuji Suzuki Eiji Funajima Kei Kitakami Kazumasa Dobashi Satomi Tamatani Yuichi Sato Takaaki Beppu Kuniaki Ogasawara Testuji Naka Source Type: research
A deep learning based holistic diagnosis system for immunohistochemistry interpretation and molecular subtyping
CONCLUSION: The holistic intelligent breast tumour diagnosis system shows improved performance in the interpretation of immunohistochemical images over pathologist-level, which can be expected to overcome the limitations of conventional manual interpretation in efficiency, precision, and repeatability.PMID:38412576 | DOI:10.1016/j.neo.2024.100976 (Source: Neoplasia)
Source: Neoplasia - February 27, 2024 Category: Cancer & Oncology Authors: Lin Fan Jiahe Liu Baoyang Ju Doudou Lou Yushen Tian Source Type: research
A deep learning based holistic diagnosis system for immunohistochemistry interpretation and molecular subtyping
CONCLUSION: The holistic intelligent breast tumour diagnosis system shows improved performance in the interpretation of immunohistochemical images over pathologist-level, which can be expected to overcome the limitations of conventional manual interpretation in efficiency, precision, and repeatability.PMID:38412576 | DOI:10.1016/j.neo.2024.100976 (Source: Neoplasia)
Source: Neoplasia - February 27, 2024 Category: Cancer & Oncology Authors: Lin Fan Jiahe Liu Baoyang Ju Doudou Lou Yushen Tian Source Type: research
Corrigendum to "Hedgehog/GLI1 Transcriptionally Regulates FANCD2 in Ovarian Tumor Cells: Its Inhibition Induces HR-Deficiency and Synergistic Lethality with PARP Inhibition." [Neoplasia Volume 23, Issue 9, September 2021, Pages 1002-1015]
Neoplasia. 2024 Feb 23;50:100978. doi: 10.1016/j.neo.2024.100978. Online ahead of print.NO ABSTRACTPMID:38401480 | DOI:10.1016/j.neo.2024.100978 (Source: Neoplasia)
Source: Neoplasia - February 24, 2024 Category: Cancer & Oncology Authors: Chinnadurai Mani Kaushlendra Tripathi Sandeep Chaudhary Ranganatha R Somasagara Rodney P Rocconi Chiquito Crasto Mark Reedy Mohammad Athar Komaraiah Palle Source Type: research
Corrigendum to "Hedgehog/GLI1 Transcriptionally Regulates FANCD2 in Ovarian Tumor Cells: Its Inhibition Induces HR-Deficiency and Synergistic Lethality with PARP Inhibition." [Neoplasia Volume 23, Issue 9, September 2021, Pages 1002-1015]
Neoplasia. 2024 Feb 23;50:100978. doi: 10.1016/j.neo.2024.100978. Online ahead of print.NO ABSTRACTPMID:38401480 | DOI:10.1016/j.neo.2024.100978 (Source: Neoplasia)
Source: Neoplasia - February 24, 2024 Category: Cancer & Oncology Authors: Chinnadurai Mani Kaushlendra Tripathi Sandeep Chaudhary Ranganatha R Somasagara Rodney P Rocconi Chiquito Crasto Mark Reedy Mohammad Athar Komaraiah Palle Source Type: research
Corrigendum to "Hedgehog/GLI1 Transcriptionally Regulates FANCD2 in Ovarian Tumor Cells: Its Inhibition Induces HR-Deficiency and Synergistic Lethality with PARP Inhibition." [Neoplasia Volume 23, Issue 9, September 2021, Pages 1002-1015]
Neoplasia. 2024 Feb 23;50:100978. doi: 10.1016/j.neo.2024.100978. Online ahead of print.NO ABSTRACTPMID:38401480 | DOI:10.1016/j.neo.2024.100978 (Source: Neoplasia)
Source: Neoplasia - February 24, 2024 Category: Cancer & Oncology Authors: Chinnadurai Mani Kaushlendra Tripathi Sandeep Chaudhary Ranganatha R Somasagara Rodney P Rocconi Chiquito Crasto Mark Reedy Mohammad Athar Komaraiah Palle Source Type: research
Who benefit from adjuvant chemotherapy in stage I lung adenocarcinoma? A multi-dimensional model for candidate selection
Neoplasia. 2024 Feb 21;50:100979. doi: 10.1016/j.neo.2024.100979. Online ahead of print.ABSTRACTBACKGROUND: Despite promising overall survival of stage I lung adenocarcinoma (LUAD) patients, 10-25 % of them still went through recurrence after surgery. [1] While it is still disputable whether adjuvant chemotherapy is necessary for stage I patients. [2] IASLC grading system for non-mucinous LUAD shows that minor high-grade patterns are significant indicator of poor prognosis. [3] Other risk factors, such as, pleura invasion, lympho-vascular invasion, STAS, etc. are also related to poor prognosis. [4-6] There still lack evide...
Source: Neoplasia - February 22, 2024 Category: Cancer & Oncology Authors: Meng-Qi Jiang Li-Qiang Qian Yu-Jia Shen Yuan-Yuan Fu Wen Feng Zheng-Ping Ding Yu-Chen Han Xiao-Long Fu Source Type: research
Who benefit from adjuvant chemotherapy in stage I lung adenocarcinoma? A multi-dimensional model for candidate selection
Neoplasia. 2024 Feb 21;50:100979. doi: 10.1016/j.neo.2024.100979. Online ahead of print.ABSTRACTBACKGROUND: Despite promising overall survival of stage I lung adenocarcinoma (LUAD) patients, 10-25 % of them still went through recurrence after surgery. [1] While it is still disputable whether adjuvant chemotherapy is necessary for stage I patients. [2] IASLC grading system for non-mucinous LUAD shows that minor high-grade patterns are significant indicator of poor prognosis. [3] Other risk factors, such as, pleura invasion, lympho-vascular invasion, STAS, etc. are also related to poor prognosis. [4-6] There still lack evide...
Source: Neoplasia - February 22, 2024 Category: Cancer & Oncology Authors: Meng-Qi Jiang Li-Qiang Qian Yu-Jia Shen Yuan-Yuan Fu Wen Feng Zheng-Ping Ding Yu-Chen Han Xiao-Long Fu Source Type: research
Single cell analysis unveils the commonality and heterogeneity between nasopharyngeal and oropharyngeal carcinoma
This study was to investigate the distinctive tumor microenvironments of NPC and OPC. Analyzing single-cell data from 10 cases of each subtype, we reveal significant differences in cellular composition, with NPC microenvironment dominated by T/NK and B cells, and OPC characterized by prevalent epithelial cells and fibroblasts. Dynamic transitions of CD8 T cells are observed in both tumor types, involving shifts from naivety to cytotoxicity, proliferation, and eventual exhaustion/exhausted states. Additionally, Tregs exhibit heightened proliferative abilities in later developmental stages, concomitant with exhaustion. These...
Source: Neoplasia - February 21, 2024 Category: Cancer & Oncology Authors: Liping Wang Shuang Li Xinran Li Guangzheng Zhuo Qian Zhang Guohong Liu Yunbao Pan Source Type: research
Single cell analysis unveils the commonality and heterogeneity between nasopharyngeal and oropharyngeal carcinoma
This study was to investigate the distinctive tumor microenvironments of NPC and OPC. Analyzing single-cell data from 10 cases of each subtype, we reveal significant differences in cellular composition, with NPC microenvironment dominated by T/NK and B cells, and OPC characterized by prevalent epithelial cells and fibroblasts. Dynamic transitions of CD8 T cells are observed in both tumor types, involving shifts from naivety to cytotoxicity, proliferation, and eventual exhaustion/exhausted states. Additionally, Tregs exhibit heightened proliferative abilities in later developmental stages, concomitant with exhaustion. These...
Source: Neoplasia - February 21, 2024 Category: Cancer & Oncology Authors: Liping Wang Shuang Li Xinran Li Guangzheng Zhuo Qian Zhang Guohong Liu Yunbao Pan Source Type: research
Targeting myeloma metabolism: How abnormal metabolism contributes to multiple myeloma progression and resistance to proteasome inhibitors
Neoplasia. 2024 Feb 15;50:100974. doi: 10.1016/j.neo.2024.100974. Online ahead of print.ABSTRACTMultiple myeloma is a hematological malignancy that has evolved from antibody-secreting B lymphocytes. Like other types of cancers, myeloma cells have acquired functional capabilities which are referred to as "Hallmarks of Cancer", and one of their most important features is the metabolic disorders. Due to the high secretory load of the MM cells, the first-line medicine proteasome inhibitors have found their pronounced effects in MM cells for blocking the degradation of misfolded proteins, leading to their accumulation in the ER...
Source: Neoplasia - February 16, 2024 Category: Cancer & Oncology Authors: Xiang Zhou Rui He Wei-Xin Hu Saiqun Luo Jingping Hu Source Type: research
Targeting myeloma metabolism: How abnormal metabolism contributes to multiple myeloma progression and resistance to proteasome inhibitors
Neoplasia. 2024 Feb 15;50:100974. doi: 10.1016/j.neo.2024.100974. Online ahead of print.ABSTRACTMultiple myeloma is a hematological malignancy that has evolved from antibody-secreting B lymphocytes. Like other types of cancers, myeloma cells have acquired functional capabilities which are referred to as "Hallmarks of Cancer", and one of their most important features is the metabolic disorders. Due to the high secretory load of the MM cells, the first-line medicine proteasome inhibitors have found their pronounced effects in MM cells for blocking the degradation of misfolded proteins, leading to their accumulation in the ER...
Source: Neoplasia - February 16, 2024 Category: Cancer & Oncology Authors: Xiang Zhou Rui He Wei-Xin Hu Saiqun Luo Jingping Hu Source Type: research
